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share the work provObjectives/design: As antiretroviral therapy (ART) rapidly expands in sub-Saharan
Africa using new efficient care models, data on costs of these approaches are lacking.
We examined costs of a streamlined HIV care delivery model within a large HIV test-
and-treat study in Uganda and Kenya.
Methods: We calculated observed per-person-per-year (ppy) costs of streamlined care
in 17 health facilities in SEARCH Study intervention communities (NCT: 01864603) via
micro-costing techniques, time-and-motion studies, staff interviews, and administrative
records. Cost categories included salaries, ART, viral load testing, recurring goods/
services, and fixed capital/facility costs. We then modeled costs under three increas-
ingly efficient scale-up scenarios: lowest-cost ART, centralized viral load testing, and
governmental healthcare worker salaries. We assessed the relationship between com-
munity-specific ART delivery costs, retention in care, and viral suppression.
Results: Estimated streamlined HIV care delivery costs were $291/ppy. ART ($117/ppy for
TDF/3TC/EFV [40%]) andviral load testing ($110/ppy for2 tests/year [39%])dominatedcosts
versus salaries ($51/ppy), recurring costs ($5/ppy), and fixed costs ($7/ppy). Optimized ART
scale-up with lowest-cost ART ($100/ppy), annual viral load testing ($24/ppy), and govern-
mental healthcare salaries ($27/ppy), lowered streamlined care cost to $163/ppy.We found
clinic-to-clinic heterogeneity in retention and viral suppression levels versus streamlined
care delivery costs, but no correlationbetween cost and either retention or viral suppression.
Conclusions: In the SEARCH Study, streamlined HIV care delivery costs were similar to
or lower than prior estimates despite including viral load testing; further optimizations
could substantially reduce costs further. These data can inform global strategies for
financing ART expansion to achieve UNAIDS 90–90–90 targets.
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2180 AIDS 2018, Vol 32 No 15IntroductionTreatment of HIV has expanded rapidly, with 19 million
of 37 million HIV-positive persons worldwide (and 14
million of 26 million in sub-Saharan Africa) now
receiving antiretroviral therapy (ART). However, HIV
remains a global pandemic with almost 2 million new
infections annually [1]. Nations are expanding progress
towards the UNAIDS ‘90–90–90’ goals: 90% of HIV-
positive individuals knowing their status, 90% of
diagnosed individuals initiating ART, and 90% individu-
als on ART achieving viral suppression [2]. However,
donor funding for ARTexpansion is anticipated to remain
stable in coming years and in some areas may be declining
[3]. This has created an urgent need for new innovative
models of HIV care delivery that capture greater
efficiencies and can serve far more patients at lower
costs per patient.
Standard HIV care delivery is structured to serve broad,
heterogeneous populations with easy to adopt, uniform
procedures. The cost of standard HIV care delivery in
Sub-Saharan Africa has declined over time with the
advent of less expensive ART medications and improved
clinical operations. Before 2009, HIV care delivery with
ART and CD4þ cell count monitoring was estimated to
cost between $643 and $1089 per person per year (ppy)
[4]. Since 2009, HIV care delivery with CD4þ cell count
monitoring has been estimated at $206–$924 ppy [5–10],
while HIV care delivery with annual viral load (VL)
monitoring has been estimated at $300–$628 ppy
[11,12].
Differentiated care is a newer term used to describe
models of HIV care that tailor clinical services to patients
depending on their needs, improve clinic efficiency, and
achieve strong and durable clinical outcomes [13].
Differentiated care models are diverse and include
innovations such as pharmacy-only ART refill visits
[8,14–16], clinic-based group visits with lay healthcare
workers [12,17–21], community-based ART delivery
[9,22–24], and community-based peer adherence sup-
port groups [25–30]. Each of these innovations has been
implemented in sub-Saharan African settings to facilitate
cost-effective ART scale-up. These innovations have
been shown to reduce the time spent per patient, improve
ART adherence, improve retention in care, and maintain
durable viral suppression.
There are limited data on the costs and cost-effectiveness
of differentiated ART delivery models. We previously
estimated the cost of a streamlined HIV care delivery
model in Uganda for patients with high CD4þ cell counts
(>500 cells/ml) that included twice per year viral load
monitoring as $320–$529 ppy [11]. In Kampala, Uganda,
an every-two-month pharmacy-only visit program cost
an estimated $520 ppy compared to $655 ppy for standard
care, with an incremental cost-effectiveness ratio of$13,500/patient [8]. This program was deemed not cost
effective as it exceeds the common cost-effectiveness
threshold of three times annual per capita GDP (i.e.
$2,116) [31]. In Jinja District, Uganda, a home
medication delivery program cost $793 ppy versus
$838 for facility-based refills [9]. In Cape Town, South
Africa, a group visit program cost $300 ppy versus $374
ppy for standard care [12]. Further, in Tete, Mozambique,
key informants reported cost savings as a primary benefit
of community-based peer adherence support groups [25].
This literature is growing, but has not yet included cost
analyses of comprehensive multicomponent models of
streamlined HIV care delivered across multiple sites. Such
data are needed to inform current discussions on the cost-
effectiveness of differentiated care scale up.
The SEARCH Study is an ongoing cluster-randomized
trial in 32 communities (approximately 10,000 persons
each) in Uganda and Kenya of an intervention combining
community-based HIV testing, linkage to care, and
streamlined HIV and general medical care delivered in
clinics. The SEARCH streamlined care model is a
patient-centric approach that aims to meet patients’
needs, reduce transit time through services, boost
efficiency for the patient and clinic, and achieve durable
viral suppression [32–34]. Streamlined HIV care seeks to
maximize the efficiency of highly trained clinical
providers, in contrast to some differentiated care models
that seek to shift care of stable patients away from clinical
providers towards lay health providers and peers. After
two years, the SEARCH intervention successfully
achieved and exceeded the UNAIDS 90–90–90 targets
for testing of more than 90% of adult community
residents [35], initiating ART in more than 90% of HIV-
positive persons, and achieving more than 90% viral
suppression among persons on ART [34].
To inform current resource allocation policies on
accelerating ART scale-up, we sought in this report to
estimate costs associated with providing streamlined care
in Ugandan and Kenyan HIV clinics in intervention
communities of the SEARCH trial. We also sought to
estimate costs of scaling up streamlined care models to
capture increasing efficiencies that are possible at regional
and national levels. Lastly, to assess healthcare value, we
sought to explore variability across communities in their
costs as compared with levels of retention in care and
viral suppression.Methods
Study setting and population
The SEARCH Study (NCT:01864603) is an ongoing
cluster-randomized trial of a universal HIV test-and-treat
intervention in 32 communities (approximately 10 000
persons each) across West Uganda, East Uganda, and
Streamlined HIV care costs in east Africa Shade et al. 2181Kenya. At baseline, communities receive a census and two
week-long community health campaign with HIV testing
(including CD4þ cell count and viral load measurement
in HIV-positive persons) and testing for other diseases
(including malaria, hypertension, and diabetes) for the
entire population [34–36].
In the 16 SEARCH Study intervention communities,
individuals diagnosed with HIVat baseline or at subsequent
annual testing campaigns are offered immediate linkage to
care and ART initiation at clinics in a streamlined model of
HIV care. Our streamlined care model has been described
previously [32,33]. Briefly, streamlined care is a multicom-
ponent HIV care model designed to reduce structural
barriers faced by patients, improve patient–clinician
relationships, improve knowledge and decrease stigma.
Central features include immediate ART initiation; a
patient-centered, welcoming, empathetic environment; co-
location of clinical, phlebotomy and medication dispensing
services; viral load monitoring with structured viral load
counseling; co-located care for noncommunicable diseases
including hypertension and diabetes; quarterly (rather than
monthly) clinic visits and ART dispensing; 24-h telephone
access to a clinician; flexible clinic hours and locations for
ART dispensation; and telephone appointment reminders
and patient tracking following missed visits [32,33].
Ethics statement
The SEARCH Study was approved by institutional
review boards at Makerere University College of Health
Sciences (Kampala, Uganda), the Kenya Medical
Research Institute (Nairobi, Kenya), the University of
California, San Francisco, and the Uganda National
Council for Science and Technology. SEARCH Study
participants provided verbal informed consent in their
preferred language.
Data collection
We collected information on resources required to
support streamlined HIV care during 2-week site visits to
17 clinics located in the 16 SEARCH Study intervention
communities from July 2015–June 2016 (second year of
intervention) using previously published methods
[11,37]. Study teams in the three regions (West Uganda,
East Uganda, and Kenya) collected cost data using
standardized tools. Teams recorded the economic value of
utilized resources regardless of funding source. Costs were
recorded as 2016 $USD. We ascertained costs in five key
categories comprising streamlined care delivery: (A)
personnel, (B) ART medications, (C) viral load testing
(D) other recurrent goods and services and (E) fixed costs
(see Supplemental Digital Content [SDC] 2 – Appendix,
for detailed description of data sources, http://links.lww.
com/QAD/B351).
Staff interviews
We interviewed SEARCH Study regional coordinators
and assistant coordinators to ascertain types and amountsof SEARCH on-site resources (e.g. SEARCH clinic staff,
ART medications) and off-site resources (e.g. SEARCH
supervisory staff, viral load testing, transportation costs)
needed for streamlined care. We interviewed health
facility managers and ascertained resources needed for
streamlined care, costs of these resources (e.g. staff salaries
and benefits, unit costs for viral load testing supplies, and
other recurring goods and services), and costs of resources
lacking administrative records (e.g. utility/facility costs).
Administrative records review
We reviewed SEARCH administrative records to
ascertain SEARCH staff salaries and benefits, costs of
ART medications, and transportation costs for SEARCH
staff and viral load test specimens. We reviewed health
facility administrative records to obtain information on
recurring goods and services (e.g. viral load and other
laboratory testing supplies) consumed during the 2-week
costing period.
Time and motion study
We conducted a time and motion (T&M) study in each
clinic to establish the proportion of total work time clinic
staff spent providing streamlined HIV care. Clinic
personnel who either directly provided or supported
streamlined HIV care completed 24-h time records daily
during the 2-week observation period. Staff recorded
information on the number of minutes spent: directly in-
person with patients; on the phone with patients;
working on tasks for patients; conducting nonclinical
SEARCH Study research work; performing other work;
and waiting for the next patient, idle or on scheduled
break.
Patient visits
The number and types of patients seen during the 2-week
observation was ascertained from clinic records. We noted
patients receiving care for HIV, noncommunicable
diseases or both conditions. To proportionally allocate
resources consumed each day, we tallied numbers of
enrolled SEARCH Study participants, non-SEARCH
Study community members, and noncommunity mem-
bers seen each day. In each study community, the number
of SEARCH Study patients served and patient visits
conducted during the previous 12 months was obtained
from clinical records.
Retention in care and viral suppression in intervention
communities
Retention in care was defined as 90 days or less late to a
scheduled appointment 12 months after baseline study
visit [38]. For each community, the probability of
retention in care at 1 year was estimated via Kaplan–
Meier survival estimates with censoring at the time of
transfer or death.
Viral suppression was defined as HIV-1 RNA less than
500 copies/ml measured during annual HIV testing
2182 AIDS 2018, Vol 32 No 15campaigns. For each community, we estimated the
proportion of HIV-positive adult community residents
with measured HIV RNA level were virologically
suppressed.
Estimation of streamlined care costs
For each study community, we estimated annual per-
patient streamlined care costs as a sum of the five cost
categories: personnel, ART medications, viral load
testing, other recurrent goods and services, and fixed
costs (Supplemental Digital Content [SDC] 2 –
Appendix, http://links.lww.com/QAD/B351).
Modeled scenarios of antiretroviral therapy
scale-up costs
We modeled the cost of providing streamlined HIV care
under a ‘base case’ scenario (outlined above), as well as
three scenarios of increasing operational efficiency that
could occur during a large scale-up of streamlined care, as
follows:
Scenario A: Base case scenario costs, but with cost of first-
line TDF/3TC/EFVantiretroviral medications set to lowest
available costs based on United Nations Development
Programme negotiated rates ($100 ppy) [39,40].
Scenario B: Costs were identical to Scenario A, except that
model included the recommended standard one viral load
test per year [41] (rather than two per year as provided in
SEARCH), cost of viral load testing was set to Uganda and
Kenya Ministry of Health (MOH) pricing of $24/test, and
transportation of viral load specimens was considered
absorbed into MOH processes (thus, noncontributory).
Scenario C: Costs were identical to Scenario B, except that
staff salaries for all positions were estimated using 2016
MOH salary scales.
Clinic heterogeneity of cost versus retention in
care and viral suppression metrics
For each clinic, we aggregated data on streamlined care
costs (outlined above) and plotted these against our
estimates of retention in care and viral suppression. We
assessed overall correlation of streamlined HIV care
delivery cost versus level of retention in care, as well as
streamlined care cost versus level of viral suppression using
Pearson’s correlation coefficient.Table 1. SEARCH intervention communities, health facilities, staff memb
SEARCH intervention communities
Health facilities assessed in SEARCH Study intervention communities
Health facility staff members assessed
HIV-positive SEARCH patients with visits during costing observation perio
HIV-positive SEARCH patients with 1 clinic visit in year of observation
Number of visits per patient per year – meanResults
Health facility characteristics
We assessed streamlined HIV care in 17 health facilities in
the 16 SEARCH Study intervention communities in
West Uganda, East Uganda and Kenya (Table 1). Clinic
staff (n ¼ 140) participated in the T&M study. More staff
members were involved in streamlined care provision in
Kenya versus Uganda. During the 2-week observations, a
total of 1313 patient visits occurred, with similar numbers
across regions. Overall, 7707 HIV-positive patients had at
least 1 streamlined HIV care visit from July 2015 to June
2016 in Kenya (n¼ 4954), West Uganda (n¼ 1807), and
East Uganda (n¼ 946). Kenya had the highest mean
number of annual visits per patient, followed by West
Uganda and East Uganda (Table 1).
Personnel effort toward streamlined care
We assessed the time spent by staff members to provide
streamlined care. Consistent with the nurse-centered
design of the streamlined care model, nurses spent the
most time devoted to patient care, averaging 15.3 min per
patient (see Table, Supplemental Digital Content [SDC]
1, http://links.lww.com/QAD/B351). Other clinic staff
spent slightly less time per patient, including clinical
officers (9.7 min), laboratory technicians (11.0 min), peer
educators (11.1 min) and data/information officers
(12.6 min; Table, SDC 1, http://links.lww.com/QAD/
B351). The distribution of staff time differed across
regions, with nurses spending more time per patient in
West and East Uganda compared to Kenya.
Total average time spent per patient was lowest in West
Uganda (36.3 min), was 68.4 min in East Uganda, and was
highest in Kenya (103.6 min). In West Uganda, nurses and
laboratory technicians provided most streamlined care
services; in East Uganda, nurses dedicated more effort
than clinical officers or laboratory technicians, but data/
information officers also triaged patients and maintained
patient files. In Kenya, data/information officers and
other staff contributed to the triage and follow-up of
patients, while peers supported education of patients.
Costs of streamlined care
Overall, provision of streamlined care cost an average of
$291 ppy and varied across regions (average $299 ppy in
West Uganda, $319 ppy in East Uganda, and $286 ppy iners, and patients included in costing activities.
West Uganda East Uganda Kenya Total
5 5 6 16
5 5 7 17
36 31 73 140
d 460 443 410 1313
1807 946 4954 7707
4.6 4.0 5.3 5.0
Streamlined HIV care costs in east Africa Shade et al. 2183Kenya, Table 2). Costs were dominated by ART
medications (40.4% of total), viral load testing (37.9%
of total), and personnel/salary costs (17.6% of costs; Table
2). Recurring and fixed costs were minor contributors to
overall costs. Personnel costs were highest in Kenya and
lowest in West Uganda. ART medication costs were
lower in Kenya ($99) than in Uganda ($150).
Modeled costs of optimized streamlined care
models for scale-up
Figure 1 shows the actual observed costs of streamlined
care (base care scenario), as well as modeled costs under
three increasingly optimized care delivery scenarios. In
scenario A (optimization to lowest available ART
pricing), streamlined care costs in Uganda are reduced
by $50.36 ppy; costs were not reduced in Kenya because
ART is already available at the optimized $100 ppy price.
In scenario B (annual optimized viral load testing and
transportation), streamlined care cost is substantially
reduced by $86 ppy in all regions. In scenario C
(governmental staff salaries), streamlined care cost is
reduced $4 ppy in West Uganda, $21 ppy in East Uganda,
and $16 ppy in Kenya. In our maximally streamlined
scenario, HIV care would cost $163 ppy overall, a 44%
reduction from the $291 ppy base case estimate.
Heterogeneity of cost, retention in care, and
viral suppression across clinics
Figure 2 shows the heterogeneity of costs across health
facilities and the relationship of cost to community
levels of retention in care and viral suppression. The
heterogeneity in costs across clinics and regions appeared
to be driven mainly by variability in personnel costs for
streamlined care. We did not observe correlation between
streamlined care costs and the proportion of patients
retained in care (R2¼ 0.003) or virologically suppressed
(R2¼ 0.031; Fig. 3).Discussion
Streamlined HIV care delivery in the SEARCH test-and-
treat trial cost an average $291 ppy, a cost similar to or
lower than prevailing estimates despite adding viral load
testing and care for noncommunicable diseases. In a series
of modeled scenarios, we found that streamlined careTable 2. Observed per person annual cost of streamlined care delivery b
Cost category West Uganda Eas
Personnel $25.62
ART $150.36 $
Viral load testing $110.17 $
Other recurring costsa $9.41
Fixed costsb $3.78
Total $299.34 $
ART, Antiretroviral therapy.
aRecurring costs included non-ART medications, utilities, and communica
bFixed costs included equipment and facilities.costs can be lowered further during scale-up by using less
expensive ART medications; optimizing viral load testing
operations; and transitioning care to Ministry of Health
(MOH)-salaried clinicians. Across clinics, we did not see
correlation between the streamlined care costs and
retention in care or viral suppression, suggesting that
different clinics may have generated varying levels of
healthcare value.
Our observed costs were similar to or lower than previous
estimates for standard and differentiated care models
across several PEPFAR-supported environments and
programs ($206–$924 ppy) [5]. These encompass data
from programs that primarily included CD4þ cell count
monitoring and that were located in Uganda [8,9], Kenya
[6], Ethiopia [7], and Zambia [10]. Our cost estimates are
also lower than those for both standard and differentiated
models of HIV care that include annual viral load
monitoring, following more modern guidelines on key
elements of HIV care ($300–$628 ppy). These included
programs in both Uganda [11] and South Africa [12], two
countries with well developed systems for viral load
monitoring. Annual viral load testing and counseling are
now recommended as core features of optimal service
delivery [41]. Our streamlined care model included
twice-a-year viral load testing and counseling as well as
care for noncommunicable and general medical condi-
tions, a comprehensive model that capitalizes on HIV
infrastructure to deliver broader health services. Yet
despite these additional expenses, costs compared
favorably to standard models of care. Furthermore, we
recently reported that this streamlined care model
achieves strong clinical outcomes, including 89% reten-
tion in care among patients newly enrolled [38], and high
viral suppression rates among stable adult community
residents [33].
The lower cost of our streamlined care model may be
related to several factors. First, our nurse-driven care
allowed patients to transit rapidly through visits,
decongesting clinics, using less clinician time, and
allowing more patients to be served. Second, many
clinics offered visits, phlebotomy and medication
dispensation by single providers, reducing staff time
spent delivering care and reducing wait time between
providers. We previously reported that visits in oury study region.
t Uganda Kenya Overall (%)
$44.01 $64.50 $51.08 (17.6)
150.36 $99.00 $117.35 (40.4)
110.36 $110.12 $110.29 (37.9)
$7.60 $5.33 $5.33 (1.8)
$6.46 $6.57 $6.57 (2.3)
318.79 $285.52 $290.62 (100)
tions fees.
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Total Cost 
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Base + Low Cost ART 
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A + MOH Centralized 
VL Testing 
Scenario C: 
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Total Estimated ART Delivery Cost ($/person/year) 
Fig. 1. Annualized per-person estimated costs for observed and optimized scenarios of streamlined HIV care delivery.streamlined care model were over one hour shorter than
standard government clinic visits [42]. Third, offering
longer 3-month (versus 1–2 month) ART refills
lengthened time between visits, reducing average daily
load and time spent by staff. This strategy has shown
positive outcomes [14–16], although issues with supply
chain management can hamper implementation. Fourth,Fig. 2. HIV care delivery costs in individual communities in Weour inclusion of patients with higher CD4þ cell counts –
a population less symptomatic and requiring less time-
intensive monitoring – may have helped create and
maintain efficiency.
Our study may inform ongoing discussions about
continued scale-up of streamlined HIV care. Our modeledst Uganda (nU5), East Uganda (nU5), and Kenya (nU6).
Streamlined HIV care costs in east Africa Shade et al. 2185
(a)
(b)
Fig. 3. Community-specific streamlined care delivery costs versus retention in care and viral suppression.scenarios show that costs could be further reduced by:
negotiating lower national ART costs, optimizing viral
load testing operations, and employing MOH-salaried
clinical staff to provide care. Ensuring lowest-price
antiretroviral drugs only modestly reduced overall costs
(6%), and the impact was greater in Uganda versus Kenya
since ART prices were substantially lower in Kenya.
Greater cost reductions (30%) occurred if viral load
specimens reached a central laboratory via the MOH
transport network (as is currently done in Uganda). This
optimization may be important as newer point-of-care
viral load technologies emerge and need integration into
national streamlined care systems. Lastly, employingMOH-salaried clinic staff reduced costs modestly (8%).
However, lower salaries must be cautiously approached as
they have been linked to lower clinician performance and
shortening of clinic hours [43], possibly challenging
streamlined care adoption. Nevertheless, the fact that our
model expanded services overall (with viral load testing and
NCD care) while remaining cost-neutral and in some cases
reducing costs, should create optimism that streamlined
care models will be crucial for ongoing ART expansion.
We noted heterogeneity in streamlined care costs across
regions. Understanding this variability is important as
individual regions and nations consider the varying
2186 AIDS 2018, Vol 32 No 15composition of their healthcare workforces, diverse
patient needs, and services to offer. We observed higher
overall ART delivery costs in Uganda, where streamlined
care was more nurse-driven and provided by a smaller
number of higher paid clinicians compared to Kenya,
where care was provided by a wider range of providers.
Task-shifting and task-sharing have been implemented to
address workforce shortages. For example, nurse-initiated
ART and use of peer health workers have both been
highly cost-effective [18]. However, the most effective
ratio of nurses, clinical officers, and lay staff remains
unclear. Future analyses directly comparing intervention
(streamlined) and control (standard) care delivery models
in the SEARCH Study will explore this question. We also
noted heterogeneity in the relative healthcare value
delivered at different clinics: higher cost clinics were not
associated with higher retention in care or viral
suppression. Future work should investigate features of
lower cost clinics that achieve higher viral suppression
(i.e., higher value) and methods for propagating this
success across entire clinic networks. Future work should
also assess how provision of different, broader, and more
integrated packages of services at clinics (i.e., services for
TB, sexual and reproductive health, and noncommunic-
able diseases apart from diabetes and hypertension), will
affect overall costs, and what potential exists for achieving
even more substantial cost efficiencies in HIV care when
services are combined. Several aspects of streamlined and
differentiated care programs such as longer visit intervals
with longer refill provision, co-location of services to
achieve shorter yet effective visit times, and proactive care
of healthier patient groups, can all increase available
clinician time, allow for delivery of broader services, and
capture greater efficiencies. These advances will be
particularly important as momentum builds for designing
broader systems to achieve universal healthcare delivery,
especially systems that build upon successful HIV-
focused infrastructure.
Our study is subject to certain limitations. First,
streamlined care in the SEARCH Study was implemen-
ted as part of a broader HIV care system in which some
patients received standard services alongside others
receiving streamlined services. To isolate streamlined
care costs, we conducted self-administered time-and-
motion studies. However, accuracy of these assessments
could be affected if staff members underestimated time
needed for certain tasks or did not fully record break/
waiting time. We minimized this risk by using simple
tools allowing staff to fully capture downtime. Second, we
did not capture which laboratory tests (other than viral
load ) and medications (other than ART) were used in
streamlined versus standard care; our analysis assumed
similar usage patterns. Since streamlined care patients are
often healthier, our costs of care may be overestimates.
Third, we did not have documentation of certain facility
costs including rent (part of fixed costs) or utilities (part of
recurring goods and services costs); these were estimatedvia interviews with clinic managers. Despite these
limitations, however, our overall cost estimates were
within range of other prevailing estimates for HIV
care delivery.
Our data from Ugandan and Kenyan clinics in the
SEARCH Study demonstrate that streamlined HIV care
that includes viral load testing and co-location of
noncommunicable disease care can be delivered at costs
similar to or lower than current prevailing ART delivery
costs. Our results add to a nascent literature on the cost of
streamlined HIV care models that include patients with
high CD4þ cell counts who are a major focus of current
expansion and scale-up of ART programs. These data can
inform resource allocation decisions in the current era of
rapidly expanding universal ART.Acknowledgements
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